Evidence map›Paper›PMID 41287346›Full record

Trial reportJournal of clinical pharmacology2026

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer.

Mark Hadigol, Jason H Williams, Haihong Shi, Derek Z Yang, Justin Hoffman, Diane D Wang

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03395197 (A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03395197 phase3active not recruitingnot on this map

A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer

TypeinterventionalSponsorPfizerRan2017 to 2027Enrolled1,054ConditionsmCRPCArmsTalazoparib with enzalutamide, Placebo with enzalutamide
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mark HadigolOncology Early Stage Development (OESD) - Clinical Pharmacology, Pfizer Inc., Collegeville, PA, USA.
Jason H WilliamsClinical Pharmacology & Pharmacometrics, Exelixis Inc., King of Prussia, PA, USA.
Haihong ShiClinical Assay Group - Translational Clinical Sciences, Pfizer Inc., Groton, CT, USA.
Derek Z YangOncology Early Stage Development (OESD) - Clinical Pharmacology, Pfizer Inc., La Jolla, CA, USA.
Justin HoffmanOncology Early Stage Development (OESD) - Clinical Pharmacology, Pfizer Inc., La Jolla, CA, USA.
Diane D WangOncology Early Stage Development (OESD) - Clinical Pharmacology, Pfizer Inc., La Jolla, CA, USA.

Funding

Pfizer
6 · The paper itself

Abstract

The poly(ADP-ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe. We provide a population pharmacokinetic model for this combination in patients with mCRPC unselected for HRR deficiencies from TALAPRO-2 (NCT03395197). The pooled dataset included 811 patients treated with enzalutamide plus either talazoparib or placebo. The final enzalutamide model was a two-compartment model with first-order absorption and inter-individual variability (IIV) on apparent clearance (CL

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsModels, BiologicalPhenylthiohydantoinPhthalazinesProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overBenzamidesHumansMaleMiddle AgedNitrilesPoly(ADP-ribose) Polymerase InhibitorsBenzamidesenzalutamideNitrilesPhenylthiohydantoinPhthalazinesPoly(ADP-ribose) Polymerase Inhibitorstalazoparibclinical pharmacologyclinical trialsoncologypopulation pharmacokineticsurology

Identifiers

PMID41287346
PMCPMC12934543

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.